The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2021 | Update on lenalidomide for MDS
Valeria Santini, MD, University of Florence, Florence, Italy, provides an update on the use of lenalidomide for the treatment of myelodysplastic syndromes (MDS), highlighting the drugs’ importance in the management of del(5q) MDS. Prof. Santini goes on to discuss whether we should use lenalidomide in patients with del(5q) that are not transfusion-dependent. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.
